An observational study in Patient Satisfaction, Graft Failure and Osteo Arthritis Knee, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-06-23.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Patient Satisfaction with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Patient Satisfaction · Sweden.
Among the 18 studies in Patient Satisfaction with a site in Sweden, this one is the 11th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2018, is one of 11 observational ones, and was the 8th registered.
882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.
Browse Patient Satisfaction studies →5 of the 18 studies in Patient Satisfaction with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 15+ · Women only
Marie Blomberg · Sites in Sweden
Ages 18+ · Women only
Umeå University · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18–90
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 150 across 227 observational studies indexed under Patient Satisfaction.
Median enrollment 142 across the 7 interventional studies, 114 across the 11 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Karolinska Institutet has 7 studies filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Patient Satisfaction with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Removal of meniscal tissue is described to result in poor knee function and a significant risk for future development of osteoarthritis. Different implants have been suggested to substitute a removed meniscus. Meniscal allograft transplantation is not widely available due to costs and availability. The semitendinosus tendon is a known graft with biological properties with potential to remodel and revascularize in an intraarticular environment such as anterior cruciate ligament reconstruction. The objective for this study was to investigate whether the semitendinosus tendon graft could function as a meniscal transplant.
Patients, both male and female, 20-50 years of age, with previous subtotal or total meniscectomy, suffering from post meniscectomy symptoms are assessed at the outpatient clinic. If inclusion criteria are met, the patients receive information regarding the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
Failure
Surgical failure of transplant defined as meniscus symptoms (joint line tenderness, swelling, locking or positive McMurray) resulting in a need for re-arthroscopy and subtotal or total resection of the transplant.
Time frame: 2 years
Improved subjective knee function
Patient reported outcome measure using the Knee Injury and Osteoarthritis Outcome Score (KOOS), 0-100 where 100 indicate best possible result.
Time frame: 2 years
Improved subjective knee function
Patient reported outcome measure using Lysholm (0-100 where 100 indicate best possible result) and Tegner activity score (0-10, where 10 indicate the highest activity level) .
Time frame: 2 years
Improved subjective knee function
Patient reported outcome measure using Euroqol 5 dimensions (EQ-5D) score (quality of life instrument with five dimensions with points from 1 to 3 where 1 indicates no problem and 3 indicate severe problems).
Time frame: 2 years
Improved subjective knee function
Patient reported outcome measure using Global score (0-10 where 10 indicate best possible result)
Time frame: 2 years
Started Jan 2018 (actual). Primary completion is estimated for Jan 2024, 72 months after the start.
Of 107 non-industry observational studies under Patient Satisfaction, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 72 months is above that.
Counting every sponsor, half of 113 studies reached it within 20 months; a quarter within 7 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.